Bristol-Myers Squibb Company (BMY) : During the past 4 weeks, traders have been relatively bearish on Bristol-Myers Squibb Company (BMY), hence the stock is down -21.96% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.18% relative to the S&P 500. The 4-week change in the price of the stock is -21.66% and the stock has fallen -2.21% in the past 1 week.
Bristol-Myers Squibb Company has dropped 15.78% during the last 3-month period . Year-to-Date the stock performance stands at -12.84%. The stock has recorded a 20-day Moving Average of 12.64% and the 50-Day Moving Average is 16.7%.
Bristol-Myers Squibb Company (NYSE:BMY): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $58.74 and $58.53 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $59.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $59.29, notching a gain of 1.04% for the day. The total traded volume was 12,134,850 . The stock had closed at $58.68 on the previous day.
Also, UBS maintains its view on Bristol-Myers Squibb Company (NYSE:BMY) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. UBS lowers the price target from $80 per share to $70 per share on Bristol-Myers Squibb Company. The rating by the firm was issued on August 19, 2016.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.